Please login to the form below

Not currently logged in
Email:
Password:

Medivir buys BioPhausia

Medivir acquires BioPhausia in €62m deal as it looks to market new hepatitis C drug

Swedish company Medivir, which develops pharmaceuticals against infectious diseases caused by viruses, is to acquire specialty pharmaceutical company BioPhausia for SEK565 million (€62m).

Medivir says that the acquisition would provide it with a well-established commercial platform from which to launch its hepatitis C drug TMC435, which should be introduced on to the market by 2013.

Ron Long, chief executive of Medivir, said: "The task in hand for us is to put ourselves in a position where we can educate the market about the virtues and advantages of TMC435.”

Under the terms of the deal, Medivir is offering a mixture of cash and new shares.

13th April 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...